In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on OmniAb (OABI – Research Report), with a price target of $11.00. The company’s shares closed yesterday at $5.42.
Willey covers the Healthcare sector, focusing on stocks such as Exelixis, Geron, and Incyte. According to TipRanks, Willey has an average return of 10.3% and a 43.01% success rate on recommended stocks.
Currently, the analyst consensus on OmniAb is a Strong Buy with an average price target of $9.33, which is a 72.14% upside from current levels. In a report released today, TD Cowen also assigned a Buy rating to the stock with a $10.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on OmniAb’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $5.48 million and a GAAP net loss of $15.74 million. In comparison, last year the company earned a revenue of $6.91 million and had a GAAP net loss of $12.6 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OmniAb (OABI) Company Description:
Avista Public Acquisition Corp II is a blank check company.
Read More on OABI:
